C-MER Medical Holdings (SEHK:3309) - Aandelenkoers, Nieuws & Analyse

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

3309 Overzicht aandelen

C-MER Medical Holdings Limited, een investeringsholding, biedt oogheelkundige diensten aan onder de merknaam C-MER Dennis Lam in Hongkong en op het Chinese vasteland.

Over het bedrijf

3309 fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	0/6
Prestaties in het verleden	3/6
Financiële gezondheid	5/6
Dividenden	0/6

Beloningen

Verhandeld tegen 73.3% onder onze schatting van de reële waarde

Dit jaar winstgevend geworden

Risicoanalyse

3309 onze risicocontroles hebben doorstaan.

C-MER Medical Holdings Limited Concurrenten

Chaoju Eye Care Holdings

SEHK:2219

HK$2.4b

Rici Healthcare Holdings

SEHK:1526

HK$1.9b

China Resources Medical Holdings

SEHK:1515

HK$6.1b

Honliv Healthcare Management Group

SEHK:9906

HK$1.4b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor C-MER Medical Holdings
Historische aandelenkoersen
Huidige aandelenkoers	HK$2.66
52 Week Hoogtepunt	HK$3.98
52 Week Laag	HK$1.81
Bèta	0.56
11 maand verandering	36.41%
3 maanden verandering	0.76%
1 Jaar Verandering	-30.37%
33 jaar verandering	-67.76%
5 jaar verandering	-47.64%
Verandering sinds IPO	-47.95%

Recent nieuws en updates

Not Many Are Piling Into C-MER Medical Holdings Limited (HKG:3309) Stock Yet As It Plummets 27%

Sep 04

Recent updates

Not Many Are Piling Into C-MER Medical Holdings Limited (HKG:3309) Stock Yet As It Plummets 27%

Sep 04

Shareholders Will Probably Hold Off On Increasing C-MER Eye Care Holdings Limited's (HKG:3309) CEO Compensation For The Time Being

May 21

C-MER Eye Care Holdings' (HKG:3309) Earnings May Just Be The Starting Point

Apr 29

C-MER Eye Care Holdings Limited's (HKG:3309) 26% Share Price Plunge Could Signal Some Risk

Feb 02

C-MER Eye Care Holdings (HKG:3309) Might Be Having Difficulty Using Its Capital Effectively

Jan 17

Rendement voor aandeelhouders

	3309	HK Healthcare	HK Markt
7D	18.8%	16.1%	8.7%
1Y	-30.4%	-21.9%	19.7%

Rendement versus industrie: 3309 presteerde slechter dan de Hong Kong Healthcare -sector, die het afgelopen jaar een rendement van -21.9 % opleverde.

Rendement versus markt: 3309 presteerde slechter dan Hong Kong Market, dat het afgelopen jaar een rendement van 19.7 % opleverde.

Prijsvolatiliteit

Is 3309's price volatile compared to industry and market?
3309 volatility
3309 Average Weekly Movement	8.0%
Healthcare Industry Average Movement	6.7%
Market Average Movement	7.1%
10% most volatile stocks in HK Market	14.7%
10% least volatile stocks in HK Market	3.6%

Stabiele aandelenkoers: 3309 heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 8% ) van 3309 is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2012	2,192	Dennis Lam	www.cmermedical.com

C-MER Medical Holdings Limited, een investeringsholding, biedt oogheelkundige diensten aan onder de merknaam C-MER Dennis Lam in Hongkong en op het Chinese vasteland. Het bedrijf is actief in vier segmenten: HK Medical Business, Verkoop van Medische Verbruiksartikelen, Oogheelkundige Business op het Chinese vasteland en Tandheelkundige Business op het Chinese vasteland. Het bedrijf levert diensten op het gebied van tandheelkunde, oncologie, medische esthetiek en laboratoria en houdt zich bezig met de verkoop van visuele hulpmiddelen, zoals brillen en lenzen, en medische verbruiksartikelen.

C-MER Medical Holdings Limited Samenvatting

Hoe verhouden de winst en inkomsten van C-MER Medical Holdings zich tot de beurswaarde?
3309 fundamentele statistieken
Marktkapitalisatie	HK$3.49b
Inkomsten(TTM)	HK$63.00m
Inkomsten(TTM)	HK$1.90b

51.9x

Koers/Winstverhouding

1.7x

P/S-verhouding

Is 3309 overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
3309 resultatenrekening (TTM)
Inkomsten	HK$1.90b
Kosten van inkomsten	HK$1.29b
Brutowinst	HK$607.94m
Overige uitgaven	HK$544.93m
Inkomsten	HK$63.00m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	0.051
Brutomarge	32.06%
Nettowinstmarge	3.32%
Schuld/Eigen Vermogen Verhouding	1.0%

Hoe presteerde 3309 op de lange termijn?

Bekijk historische prestaties en vergelijking

3309 Overzicht aandelen

Beloningen

Risicoanalyse

C-MER Medical Holdings Limited Concurrenten

SEHK:2219

HK$2.4b

SEHK:1526

HK$1.9b

SEHK:1515

HK$6.1b

SEHK:9906

HK$1.4b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Investor sentiment improves as stock rises 32%

Chairman & CEO recently bought HK$776k worth of stock

Investor sentiment deteriorates as stock falls 18%

Not Many Are Piling Into C-MER Medical Holdings Limited (HKG:3309) Stock Yet As It Plummets 27%

First half 2024 earnings released: EPS: HK$0.025 (vs HK$0.024 in 1H 2023)

C-MER Medical Holdings Limited to Report First Half, 2024 Results on Aug 29, 2024

Recent updates

Investor sentiment improves as stock rises 32%

Chairman & CEO recently bought HK$776k worth of stock

Investor sentiment deteriorates as stock falls 18%

Not Many Are Piling Into C-MER Medical Holdings Limited (HKG:3309) Stock Yet As It Plummets 27%

First half 2024 earnings released: EPS: HK$0.025 (vs HK$0.024 in 1H 2023)

C-MER Medical Holdings Limited to Report First Half, 2024 Results on Aug 29, 2024

Chairman & CEO recently bought HK$841k worth of stock

Shareholders Will Probably Hold Off On Increasing C-MER Eye Care Holdings Limited's (HKG:3309) CEO Compensation For The Time Being

C-MER Eye Care Holdings' (HKG:3309) Earnings May Just Be The Starting Point

C-MER Eye Care Holdings Limited, Annual General Meeting, May 28, 2024

New major risk - Revenue and earnings growth

C-MER Eye Care Holdings Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

C-MER Eye Care Holdings Limited's (HKG:3309) 26% Share Price Plunge Could Signal Some Risk

C-MER Eye Care Holdings (HKG:3309) Might Be Having Difficulty Using Its Capital Effectively

Price target decreased by 12% to HK$4.50

First half 2023 earnings released: EPS: HK$0.024 (vs HK$0.012 in 1H 2022)

C-MER Eye Care Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2023

C-MER Eye Care Holdings Limited to Report First Half, 2023 Results on Aug 30, 2023

C-MER Eye Care Holdings Limited Announces Board Changes, Effective July 3, 2023

Insufficient new directors

Now 21% undervalued after recent price drop

Now 22% undervalued after recent price drop

A Look At The Intrinsic Value Of C-MER Eye Care Holdings Limited (HKG:3309)

Full year 2022 earnings released: HK$0.018 loss per share (vs HK$0.019 profit in FY 2021)

Now 22% undervalued

Capital Allocation Trends At C-MER Eye Care Holdings (HKG:3309) Aren't Ideal

Insufficient new directors

Chairman & CEO recently bought HK$1.9m worth of stock

Chairman & CEO recently bought HK$1.3m worth of stock

Insufficient new directors

Is C-MER Eye Care Holdings (HKG:3309) A Risky Investment?

First half 2022 earnings released: EPS: HK$0.012 (vs HK$0.012 in 1H 2021)

Insufficient new directors

C-MER Eye Care Holdings Limited to Report First Half, 2022 Results on Aug 30, 2022

C-MER Eye Care Holdings Limited, Annual General Meeting, May 24, 2022

Full year 2021 earnings released: EPS: HK$0.019 (vs HK$0.006 loss in FY 2020)

C-MER Eye Care Holdings Limited Recommends No Payment of Any Final Dividend for the Year Ended 31 December 2021

C-MER Eye Care Holdings Limited (SEHK:3309) entered into the Sale and Purchase agreements to acquire Champion Eye Centre Limited from Yeung, Hung, Pauline Chan, Ko, DN Chan,Yip, and the Estate of Cheung for HKD 56.02 million.

Executive Director exercised options to buy HK$1.7m worth of stock.

C-MER Eye Care Holdings Limited (SEHK:3309) entered into an Equity Transfer Agreement to acquire 7% stake in Shenzhen Aikangjian Group Co., Ltd. from Shenzhen Capital Group Co., Ltd. for CNY 45.5 million

First half 2021 earnings released: EPS HK$0.012 (vs HK$0.02 loss in 1H 2020)

C-MER Eye Care Holdings Limited Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended June 30, 2021

Independent Non-Executive Director recently bought HK$1.6m worth of stock

C-MER Eye Care Holdings Limited Approves Final Dividend for the Year Ended 31 December 2020

Upcoming dividend of HK$0.02 per share

Full year 2020 earnings released: HK$0.006 loss per share (vs HK$0.04 profit in FY 2019)

Full year 2020 earnings released: HK$0.006 loss per share (vs HK$0.04 profit in FY 2019)

C-MER Eye Care Holdings Limited to Report Fiscal Year 2020 Results on Mar 31, 2021

New 90-day high: HK$6.89

C-MER Eye Care Holdings Limited (SEHK:3309) signed a Purchase Agreement to acquire 60% stake in CAD/CAM Restorative Dental Centre Limited from YIU Bun Ka for HK$12.9 million.

New 90-day high: HK$6.44

Update: C-MER Eye Care Holdings (HKG:3309) Stock Gained 25% In The Last Year

Independent Non-Executive Director recently bought HK$1.8m worth of stock

C-MER Eye Care Holdings Limited Announces Board Changes

New 90-day low: HK$5.58

Independent Non-Executive Director recently bought HK$208k worth of stock

New 90-day low: HK$5.86

First half earnings released

Independent Non-Executive Director recently bought HK$138k worth of stock